Company Events | 2022 China ChemPharm CMC Innovation Summit Came to a Successful End in Shanghai

Dec.08.2022

China’s drug development is gradually moving toward innovation and originality, with a majority of new drugs being small molecule drugs. Though domestic small molecule innovative drug industry improves, there are still challenges and difficulties, including insufficient innovation, insufficient investment in R&D, and limited product market space. Co-hosted by LinkChem and Pharnex, "2022 China ChemPharm CMC Innovation Summit" was successfully held in Kerry Hotel Pudong, Shanghai on December 1-2, 2022.

The summit brought together leading talents and experts. They shared their thoughts on five topics: small molecule innovative drug development, CNS disease drug development, the Bund pharmaceutical company gathering, antiviral/ infective drug development, small molecule CMC development. Small molecule drug innovation was widely analyzed at home and abroad, and various opportunities, challenges and trends of small molecules were discussed from a forward-looking perspective, bringing an academic feast in this field.

As one of the event organizers, LinkChem was actively participated in the forum. Dr. Lu, CEO of LinkChem, Dr. Zhang, General Manager of LinkChem, Dr. Zhong, CTO of LinkChem, and Mr. Yang, General Manager of Shanghai XFlow Chemical Technology made keynote speeches and in-depth exchanges with industry colleagues. They shared industry experience in small molecule process development, green continuous flow technology application, promoting new cooperation intentions, and discussing future development trends of small molecule drugs.

At the beginning of the summit, Dr. Lu, CEO of LinkChem, gave an opening speech, kicking off the China Chemical Pharmaceutical CMC Innovation Summit 2022. Dr. Lu indicated that the development of new drugs was gradually moving towards originality and innovation in China, and small molecule innovative drugs were the main force of drug development. This summit provided an opportunity to communicate and cooperate for the development of new technologies and strategies of small molecule drugs. The speech fully expressed a warm welcome to the guests and colleagues. Later the same day, Dr. Lu delivered a speech entitled "Annual API Trends Review 2022", using specific data to explain the development trend of APIs/ intermediates in 2022, and shared valuable insights on how to adopt differentiation strategies to enhance competitiveness in the future.

In the main session on December 1, Dr. Zhang, General Manager of LinkChem, served as the moderator of the panel discussion, facilitating the “Small Molecule Innovative Drug R&D Layout and Development Trend” discussion with small molecule innovative drug experts and R&D company leaders.

Dr. Zhong, CTO of LinkChem, gave a speech on the theme of "Art of GMP Process Route Design

: Innovation and Transcendence", highlighting the technical elements of GMP process route design and natural product (total) synthesis. Combined with case studies, Dr. Zhong discussed the exploration process of synthetic route and process production. He also participated in the panel discussion on “Small Molecule Innovative Drug R&D Layout and Development Trend”, sharing his technical experience and views about the challenges and opportunities of small molecule drug industry.

Mr. Yang, General Manager of Shanghai XFlow Chemical Technology, gave a speech in the title of " Application of Continuous Flow in CDMO ", talking about the nature of flow chemistry and reaction equipment from the perspectives of continuous flow and microreaction technology. Despite the characteristics of different reactors in the continuous flow laboratory, the speech featured the industrialization of flow chemistry and its application and advantages in various chemical reactions.

During the summit, the LinkChem team was enthusiastic and professional in receiving every visitor with a lively booth atmosphere. An endless stream of attendees came to our booth for information exchanges and discussions, and visiting partners expressed their willingness to work and deepen cooperation with LinkChem.